US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Veradermics, Inc.

98.46

+0.95000.97%

Post-market: 98.460.00000.00%19:57 EDT

Volume:427.30K

Turnover:41.70M

Market Cap:4.11B

PE:-15.28

High:100.55

Open:97.80

Low:95.44

Close:97.51

52wk High:131.24

52wk Low:32.00

Shares:41.78M

Float Shares:32.29M

Volume Ratio:0.77

T/O Rate:1.32%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-6.4439

EPS(LYR):-111.9114

ROE:-72.06%

ROA:-43.45%

PB:5.06

PE(LYR):-0.88

Loading ...

Overview Company News Filings

Veradermics Inc - Vdphl01 Shows Favorable Safety Profile With Adverse Event Rates Similar to Placebo

THOMSON REUTERS

Veradermics Inc - Vdphl01 Meets All Primary and Key Secondary Endpoints With High Statistical Significance

THOMSON REUTERS

Veradermics’ Oral Vdphl01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss

THOMSON REUTERS

Veradermics to report Phase 2/3 VDPHL01 trial topline results in male hair loss

Veradermics to Hold Conference Call to Discuss Topline Results From Phase 2/3 ‘302’ Study of Vdphl01 in Males With Mild-to-Moderate Pattern Hair Loss

THOMSON REUTERS

Veradermics Is Maintained at Outperform by Leerink Partners

Veradermics Q4 EPS $(0.62) Beats $(0.66) Estimate

Benzinga Earnings

BRIEF-Veradermics Reports Fourth Quarter And Full Year 2025 Financial Results

Earnings Flash (MANE) Veradermics Posts Q4 Net Loss $21.8M

MT Newswires Live

Veradermics reports Q4 net loss $21.8M vs $5.7M last year

Veradermics FY25 net loss widens to $70 million; R&D expense climbs to $62 million

Veradermics Inc - Q4 Net Loss $21.8 Mln

THOMSON REUTERS

Press Release: Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates

Veradermics management to meet with Jefferies

Senior Living REIT IPO Shows Wall Street Remains Hot for Yield Plays -- Barrons.com

Veradermics to present three VDPHL01 and hair-loss patient experience abstracts at AAD annual meeting

Veradermics Initiated at Buy by Jefferies

Citigroup Initiates VeraDermics at Buy With $85 Price Target

MT Newswires Live

Jefferies Initiates VeraDermics at Buy With $75 Price Target

MT Newswires Live

Cantor Fitzgerald Initiates VeraDermics at Overweight

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/MANE/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MANE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MANE\",,,,,undefined,":{"symbol":"MANE","market":"US","secType":"STK","nameCN":"Veradermics, Inc.","latestPrice":98.46,"timestamp":1788379200000,"preClose":97.51,"halted":0,"volume":427303,"hourTrading":{"tag":"盘后","latestPrice":98.46,"preClose":98.46,"latestTime":"19:57 EDT","volume":5444,"amount":536172.7282,"timestamp":1788393435577,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.009742590503537981,"floatShares":32290700,"shares":41778687,"eps":-6.443948,"marketStatus":"Not Yet Opened","change":0.95,"latestTime":"09-02 16:00:00 EDT","open":97.8,"high":100.55,"low":95.4427,"amount":41701942.344928004,"amplitude":0.052377,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.443948,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788422400000},"marketStatusCode":0,"adr":0,"listingDate":1770181200000,"exchange":"NYSE","adjPreClose":97.51,"preHourTrading":{"tag":"盘前","latestPrice":97.98,"preClose":97.51,"latestTime":"09:15 EDT","volume":1565,"amount":155354.2322,"timestamp":1788354919785,"change":0.47,"changeRate":0.00482,"amplitude":0.171162},"postHourTrading":{"tag":"盘后","latestPrice":98.46,"preClose":98.46,"latestTime":"19:57 EDT","volume":5444,"amount":536172.7282,"timestamp":1788393435577,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.768849,"impliedVol":1.0942,"impliedVolPercentile":0.8889},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MANE\",,,,,undefined,":{"symbol":"MANE","floatShares":32290700,"roa":"-43.45%","roe":"-72.06%","lyrEps":-111.911419,"volumeRatio":0.768849,"shares":41778687,"dividePrice":0,"high":100.55,"amplitude":0.052377,"preClose":97.51,"low":95.4427,"week52Low":32,"pbRate":"5.06","week52High":131.2399,"institutionHeld":0,"latestPrice":98.46,"eps":-6.443948,"divideRate":0,"volume":427303,"delay":0,"ttmEps":-6.443948,"open":97.8,"prevYearClose":17,"prevWeekClose":97.93,"prevMonthClose":98.41,"prevQuarterClose":122.94,"fiveDayClose":102.8,"twentyDayClose":111.34,"sixtyDayClose":90.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MANE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"MANE","fiscalQuarterEnding":"2026/06","expectedEps":-0.58,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.58}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MANE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MANE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4286,"buy":0.5714,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5714,"analysts":7,"updateTime":1784174400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MANE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MANE","date":"2026-09-01","current":-15.279453,"percent":0.611111,"low":-67.545361,"twenty":-54.261515,"median":-47.237246,"eighty":-33.984616,"high":-9.296992,"avg":-45.302162,"sd":10.967977,"marketCap":4111583183},"quantilePoints":[{"date":"2026-02-06","current":-25.786263,"twenty":-25.079893,"median":-17.8457,"eighty":-10.368249,"marketCap":1387507243},{"date":"2026-02-13","current":-30.838039,"twenty":-29.065754,"median":-25.786263,"eighty":-19.198356,"marketCap":1659333205},{"date":"2026-02-20","current":-33.530469,"twenty":-32.062123,"median":-28.069277,"eighty":-25.043809,"marketCap":1804207481},{"date":"2026-02-27","current":-29.776333,"twenty":-31.085076,"median":-29.967163,"eighty":-25.732137,"marketCap":1602204947},{"date":"2026-03-06","current":-33.738647,"twenty":-32.654736,"median":-30.560469,"eighty":-26.152655,"marketCap":1815409101},{"date":"2026-03-13","current":-35.785726,"twenty":-33.721993,"median":-31.049686,"eighty":-27.249057,"marketCap":1925558357},{"date":"2026-03-20","current":-39.491287,"twenty":-35.53175,"median":-31.816474,"eighty":-28.546698,"marketCap":2124947181},{"date":"2026-03-27","current":-46.874652,"twenty":-39.507941,"median":-32.867771,"eighty":-29.468231,"marketCap":2522231279},{"date":"2026-04-02","current":-31.356106,"twenty":-39.513493,"median":-32.867771,"eighty":-29.852665,"marketCap":2194770608},{"date":"2026-04-10","current":-31.99758,"twenty":-38.92088,"median":-32.857362,"eighty":-30.17702,"marketCap":2239670594},{"date":"2026-04-17","current":-39.540857,"twenty":-39.536494,"median":-33.608872,"eighty":-30.279902,"marketCap":2767662294},{"date":"2026-04-24","current":-36.942854,"twenty":-39.536494,"median":-33.738647,"eighty":-30.421684,"marketCap":2585815082},{"date":"2026-05-01","current":-52.813611,"twenty":-40.831905,"median":-34.49692,"eighty":-30.615983,"marketCap":3696688710},{"date":"2026-05-08","current":-63.45616,"twenty":-42.963163,"median":-35.411007,"eighty":-30.844978,"marketCap":4441613943},{"date":"2026-05-15","current":-51.496667,"twenty":-46.59847,"median":-35.988193,"eighty":-30.890717,"marketCap":4368307751},{"date":"2026-05-22","current":-50.831536,"twenty":-50.412067,"median":-36.702792,"eighty":-31.015444,"marketCap":4311886693},{"date":"2026-05-29","current":-50.670085,"twenty":-50.670085,"median":-37.508333,"eighty":-31.226637,"marketCap":4298191318},{"date":"2026-06-05","current":-49.857433,"twenty":-50.482929,"median":-39.295461,"eighty":-31.282151,"marketCap":4229256485},{"date":"2026-06-12","current":-46.493546,"twenty":-50.049515,"median":-39.519044,"eighty":-31.356106,"marketCap":3943908052},{"date":"2026-06-18","current":-45.24748,"twenty":-50.006173,"median":-40.004977,"eighty":-31.7244,"marketCap":3838207974},{"date":"2026-06-26","current":-58.79168,"twenty":-50.634624,"median":-40.906894,"eighty":-31.961359,"marketCap":4987121867},{"date":"2026-07-02","current":-63.278505,"twenty":-51.067836,"median":-42.661209,"eighty":-32.20951,"marketCap":5367725705},{"date":"2026-07-10","current":-61.520221,"twenty":-53.048338,"median":-44.057315,"eighty":-32.416525,"marketCap":5218575793},{"date":"2026-07-17","current":-52.123009,"twenty":-54.2625,"median":-44.976596,"eighty":-32.698555,"marketCap":4421438445},{"date":"2026-07-24","current":-57.062948,"twenty":-54.490042,"median":-45.472923,"eighty":-32.869852,"marketCap":4840478675},{"date":"2026-07-31","current":-51.531989,"twenty":-54.856474,"median":-45.794173,"eighty":-33.139095,"marketCap":4371304020},{"date":"2026-08-07","current":-53.511905,"twenty":-54.832834,"median":-46.684099,"eighty":-33.593192,"marketCap":4539254342},{"date":"2026-08-14","current":-50.036631,"twenty":-54.832834,"median":-47.316049,"eighty":-33.69117,"marketCap":4637595096},{"date":"2026-08-21","current":-47.476198,"twenty":-54.602336,"median":-47.561116,"eighty":-33.713665,"marketCap":4400283923},{"date":"2026-08-28","current":-45.893958,"twenty":-54.263485,"median":-47.316049,"eighty":-33.861631,"marketCap":4253635646},{"date":"2026-09-01","current":-44.361305,"twenty":-54.261515,"median":-47.237246,"eighty":-33.984616,"marketCap":4111583183}],"updateTime":1788395053340},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MANE\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2630228398","title":"Veradermics Inc - Vdphl01 Shows Favorable Safety Profile With Adverse Event Rates Similar to Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2630228398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630228398?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA2PRKW0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630215398","title":"Veradermics Inc - Vdphl01 Meets All Primary and Key Secondary Endpoints With High Statistical Significance","url":"https://stock-news.laohu8.com/highlight/detail?id=2630215398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630215398?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA2PRKW0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630039895","title":"Veradermics’ Oral Vdphl01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2630039895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630039895?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:00","pubTimestamp":1777287601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA2PRKW0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630336733","title":"Veradermics to report Phase 2/3 VDPHL01 trial topline results in male hair loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2630336733","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630336733?lang=en_us&edition=fundamental","pubTime":"2026-04-27 04:00","pubTimestamp":1777233624,"startTime":"0","endTime":"0","summary":"Veradermics scheduled investor call and webcast for April 27, 2026, to present topline results from Part A of Phase 2/3 ‘302’ trial of VDPHL01 in males with mild-to-moderate pattern hair loss.Update will cover initial readout from randomized, double-blind, placebo-controlled study of extended-release oral minoxidil tablet.Presentation timing signals near-term catalyst for program positioning ahead of potential late-stage development and commercialization planning.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire  on April 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nNDL9Rnkw7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630833673","title":"Veradermics to Hold Conference Call to Discuss Topline Results From Phase 2/3 ‘302’ Study of Vdphl01 in Males With Mild-to-Moderate Pattern Hair Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2630833673","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630833673?lang=en_us&edition=fundamental","pubTime":"2026-04-27 04:00","pubTimestamp":1777233601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260426:nTUA6HXHK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629331040","title":"Veradermics Is Maintained at Outperform by Leerink Partners","url":"https://stock-news.laohu8.com/highlight/detail?id=2629331040","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629331040?lang=en_us&edition=fundamental","pubTime":"2026-04-22 22:19","pubTimestamp":1776867540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MANE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 10:19 ET (14:19 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623451533","title":"Veradermics Q4 EPS $(0.62) Beats $(0.66) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623451533","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623451533?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:45","pubTimestamp":1774878312,"startTime":"0","endTime":"0","summary":"Veradermics (NYSE:MANE) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.66) by 6.06 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51538413/veradermics-q4-eps-0-62-beats-0-66-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623777312","title":"BRIEF-Veradermics Reports Fourth Quarter And Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2623777312","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623777312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:02","pubTimestamp":1774872120,"startTime":"0","endTime":"0","summary":"BRIEF-Veradermics Reports Fourth Quarter And Full Year 2025 Financial Results March 30 (Reuters) - Veradermics Inc MANE.N:VERADERMICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND HI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA8GDFWW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623370312","title":"Earnings Flash (MANE) Veradermics Posts Q4 Net Loss $21.8M","url":"https://stock-news.laohu8.com/highlight/detail?id=2623370312","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623370312?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:44","pubTimestamp":1774871093,"startTime":"0","endTime":"0","summary":"Earnings Flash (MANE) Veradermics Posts Q4 Net Loss $21.8M","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623312847","title":"Veradermics reports Q4 net loss $21.8M vs $5.7M last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2623312847","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623312847?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:36","pubTimestamp":1774870611,"startTime":"0","endTime":"0","summary":"Cash, cash equivalents, and marketable securities totaled $141.9 million as of December 31, 2025. “2025 was a landmark year for Veradermics (MANE),...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veradermics-reports-q4-net-loss-21-8m-vs-5-7m-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veradermics-reports-q4-net-loss-21-8m-vs-5-7m-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623431410","title":"Veradermics FY25 net loss widens to $70 million; R&D expense climbs to $62 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623431410","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623431410?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:31","pubTimestamp":1774870312,"startTime":"0","endTime":"0","summary":"Veradermics posted a Q4 net loss of $21.8 million, widening from a year earlier.R&D expense jumped to $62.1 million, due to higher VDPHL01 clinical development spending and increased headcount.Cash, cash equivalents, and marketable securities totaled $141.9 million; an upsized IPO in February raised gross proceeds of about $295 million.Management expects cash runway into 2029, with VDPHL01 Study 302 topline data due in H1 2026 and Study 304 topline data expected in H2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire  on March 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL63lYDh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314763","title":"Veradermics Inc - Q4 Net Loss $21.8 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314763?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA8GDFWW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623314427","title":"Press Release: Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2623314427","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623314427?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:30","pubTimestamp":1774870200,"startTime":"0","endTime":"0","summary":"Enrollment completed in two pivotal trials of VDPHL01 in male patients; topline data expected from Study 302 in 1H 2026 and Study 304 confirmatory trial in 2H 2026. Enrollment on-track in Study 306, the first-ever Phase 2/3 trial of an oral treatment specifically for female pattern hair loss. Mark Neumann, seasoned biopharmaceutical commercial leader with more than 30 years of experience launching and scaling blockbuster therapies, appointed Chief Commercial and Strategy Officer. Upsized IPO of $294.8 million closed in February 2026; pro forma cash, cash equivalents and marketable securities expected to fund planned operations into 2029, through multiple anticipated Phase 3 readouts and the anticipated launch of VDPHL01, if approved. Veradermics, Incorporated , a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today reported financial results for the fourth quarter and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","MANE","IPO","R","BK4007","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622709054","title":"Veradermics management to meet with Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2622709054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622709054?lang=en_us&edition=fundamental","pubTime":"2026-03-25 02:40","pubTimestamp":1774377614,"startTime":"0","endTime":"0","summary":"Dinner Meeting to be held in New York on March 24 at 6 pm hosted by Jefferies. Published first on TheFly – the ultimate source for real-time, marke...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veradermics-management-to-meet-with-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veradermics-management-to-meet-with-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620302947","title":"Senior Living REIT IPO Shows Wall Street Remains Hot for Yield Plays -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2620302947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620302947?lang=en_us&edition=fundamental","pubTime":"2026-03-20 23:46","pubTimestamp":1774021560,"startTime":"0","endTime":"0","summary":"Real estate stocks have been winners in this oil- and Iran-obsessed volatile stock market. That bodes well for Janus Living, a senior housing real estate investment trust that is set to debut Friday morning.Janus Living, a carve-out of medical REIT Healthpeak Properties, priced its initial public offering at $20 a share, the high end of its projected range. The company also upped the size of its stock sale, from 37 million shares to 42 million shares. Janus Living is raising $840 million from the IPO and would be valued at $5.1 billion at the $20 price. The stock will trade with the ticker symbol of JAN on the New York Stock Exchange.Investors love the big dividends. Healthpeak, which will still own more than 80% of Janus Living following the IPO, pays a dividend that yields nearly 7% for example.The performance of several of this year's deals so far is a relatively promising sign following a solid year for IPOs in 2025. And investors are eagerly awaiting more  deals ahead. Elon Musk's","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OFRM","BOBS","JAN","FPS","BK4585","BK4588","CFA.SI","BK4212","BK4203","BK4120","BK4225","BK6142","REIT","WELL","MANE","BK4007","BK4182","8C8U.SI","BK4178"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620590237","title":"Veradermics to present three VDPHL01 and hair-loss patient experience abstracts at AAD annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620590237","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620590237?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:00","pubTimestamp":1773831646,"startTime":"0","endTime":"0","summary":"Veradermics said three abstracts will be presented at the American Academy of Dermatology Annual Meeting in Denver, Colorado, on March 27-31, 2026. Two social listening presentations are scheduled for March 27, 2026, at 11:25-11:30am MT and 2:15-2:20pm MT at the Colorado Convention Center.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire  on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6hRKb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616533732","title":"Veradermics Initiated at Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2616533732","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616533732?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:13","pubTimestamp":1772457180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MANE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 08:13 ET (13:13 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616105332","title":"Citigroup Initiates VeraDermics at Buy With $85 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2616105332","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616105332?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:57","pubTimestamp":1772456228,"startTime":"0","endTime":"0","summary":"Citigroup Initiates VeraDermics at Buy With $85 Price Target","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616233211","title":"Jefferies Initiates VeraDermics at Buy With $75 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2616233211","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616233211?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:56","pubTimestamp":1772456193,"startTime":"0","endTime":"0","summary":"Jefferies Initiates VeraDermics at Buy With $75 Price Target","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MANE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616332110","title":"Cantor Fitzgerald Initiates VeraDermics at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332110","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616332110?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:56","pubTimestamp":1772456192,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald Initiates VeraDermics at Overweight","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","MANE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":124,"code":"91000000","status":"200"}]}}